JP2019023184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019023184A5 JP2019023184A5 JP2018134424A JP2018134424A JP2019023184A5 JP 2019023184 A5 JP2019023184 A5 JP 2019023184A5 JP 2018134424 A JP2018134424 A JP 2018134424A JP 2018134424 A JP2018134424 A JP 2018134424A JP 2019023184 A5 JP2019023184 A5 JP 2019023184A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding
- domain
- bispecific
- polypeptide molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- -1 CD32b Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000030279 gene silencing Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 108010009992 CD163 antigen Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100035716 Glycophorin-A Human genes 0.000 claims 1
- 102000009485 HLA-D Antigens Human genes 0.000 claims 1
- 108010048896 HLA-D Antigens Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980744 Homo sapiens C-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims 1
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 claims 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 108010073816 IgE Receptors Proteins 0.000 claims 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102100025390 Integrin beta-2 Human genes 0.000 claims 1
- 102100032999 Integrin beta-3 Human genes 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 claims 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 claims 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| US62/532,713 | 2017-07-14 | ||
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017115966.5 | 2017-07-14 | ||
| DE102017119866.0 | 2017-08-30 | ||
| DE102017119866 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| US62/658,318 | 2018-04-16 | ||
| DE102018108995.3 | 2018-04-16 | ||
| DE102018108995 | 2018-04-16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177784A Division JP2021019626A (ja) | 2017-07-14 | 2020-10-23 | 改善された二重特異性ポリペプチド分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019023184A JP2019023184A (ja) | 2019-02-14 |
| JP2019023184A5 true JP2019023184A5 (https=) | 2019-06-20 |
| JP6784724B2 JP6784724B2 (ja) | 2020-11-11 |
Family
ID=62951983
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501174A Pending JP2020530762A (ja) | 2017-07-14 | 2018-07-13 | 改善された二重特異性ポリペプチド分子 |
| JP2018134424A Active JP6784724B2 (ja) | 2017-07-14 | 2018-07-17 | 改善された二重特異性ポリペプチド分子 |
| JP2023083663A Pending JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
| JP2023198791A Pending JP2024023385A (ja) | 2017-07-14 | 2023-11-24 | 改善された二重特異性ポリペプチド分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501174A Pending JP2020530762A (ja) | 2017-07-14 | 2018-07-13 | 改善された二重特異性ポリペプチド分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083663A Pending JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
| JP2023198791A Pending JP2024023385A (ja) | 2017-07-14 | 2023-11-24 | 改善された二重特異性ポリペプチド分子 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US20190016803A1 (https=) |
| EP (3) | EP3428194B1 (https=) |
| JP (4) | JP2020530762A (https=) |
| KR (2) | KR20200026995A (https=) |
| CN (2) | CN110914307A (https=) |
| AU (2) | AU2018298881B2 (https=) |
| BR (2) | BR112020000769A2 (https=) |
| CA (2) | CA3069842A1 (https=) |
| CO (2) | CO2020001029A2 (https=) |
| CR (2) | CR20200014A (https=) |
| CY (2) | CY1124091T1 (https=) |
| DK (2) | DK3428194T3 (https=) |
| ES (2) | ES2871146T3 (https=) |
| HR (1) | HRP20211744T1 (https=) |
| HU (2) | HUE057110T2 (https=) |
| LT (2) | LT3428194T (https=) |
| MA (1) | MA46299B1 (https=) |
| MD (2) | MD3428194T2 (https=) |
| MX (1) | MX2020011744A (https=) |
| PE (2) | PE20200615A1 (https=) |
| PL (2) | PL3428194T3 (https=) |
| PT (2) | PT3428194T (https=) |
| RS (2) | RS61817B1 (https=) |
| SG (2) | SG11202000025SA (https=) |
| SI (2) | SI3428194T1 (https=) |
| TW (2) | TWI762677B (https=) |
| WO (2) | WO2019012141A1 (https=) |
| ZA (1) | ZA202000842B (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| MX2020012124A (es) | 2018-05-14 | 2021-04-19 | Immunocore Ltd | Polipeptidos de unión bifuncional. |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| JP7738914B2 (ja) * | 2019-12-05 | 2025-09-16 | アーベル リミテッド | ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| AU2022318257A1 (en) | 2021-07-27 | 2024-02-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding ct45 |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| KR20240116828A (ko) * | 2021-12-14 | 2024-07-30 | 씨디알-라이프 아게 | 이중 mhc-표적화 t 세포 관여자 |
| KR20240149435A (ko) | 2022-02-20 | 2024-10-14 | 이뮤노코어 리미티드 | Hiv 특이적 결합 분자 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| US20250354995A1 (en) * | 2022-04-29 | 2025-11-20 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4569324A1 (en) | 2022-08-08 | 2025-06-18 | Immatics Biotechnologies GmbH | Guided positional scanning method |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| US12195534B2 (en) | 2023-01-06 | 2025-01-14 | Immunocore Limited | Binding molecules |
| US12134647B2 (en) | 2023-01-06 | 2024-11-05 | Immunocore Limited | Binding molecules |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025087436A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | 基于t细胞受体的多特异性多肽分子及其组合物和用途 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025094054A1 (en) * | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| DK1438400T3 (da) | 2001-10-01 | 2009-10-05 | Dyax Corp | Flerkædede eukaryote display-vektorer og anvendelser deraf |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| NZ561338A (en) | 2005-04-01 | 2010-04-30 | Immunocore Ltd | High affinity HIV T cell receptors |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PL2002003T3 (pl) | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Wektor genetyczny zawierający mi-RNA |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| CN102958942A (zh) | 2009-12-29 | 2013-03-06 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| JP2015537043A (ja) | 2012-11-30 | 2015-12-24 | ロシュ グリクアート アーゲー | 多機能タンパク質を含むがん細胞標的化ｍｈｃクラスｉを用いた循環性ウイルス特異的細胞傷害性ｔ細胞によるがん細胞の除去 |
| MX375359B (es) | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| CA2896359A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| JP6676521B2 (ja) * | 2013-03-14 | 2020-04-08 | マクロジェニクス，インコーポレーテッド | 二重特異性分子、薬学的組成物及びそれらの使用 |
| HRP20250551T1 (hr) | 2013-11-27 | 2025-06-20 | Zymeworks Bc Inc. | Bispecifični antigen-vezujući konstrukti koji ciljaju her2 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| TR201907352T4 (tr) | 2014-03-25 | 2019-06-21 | Merial Inc | Atenüe edi̇lmi̇ş histophilus somni i̇çeren i̇mmünoloji̇k bi̇leşi̇mler |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| US10744157B2 (en) | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
| EP3842450A1 (en) * | 2015-10-23 | 2021-06-30 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US11034767B2 (en) | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
| EP3472208B9 (en) | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | T cell receptors and uses thereof |
| EP3475938B1 (en) | 2016-06-27 | 2020-12-23 | The Procter and Gamble Company | Apparatus and method for assessing tooth-sensitivity treatment by oral-care product |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018026018A1 (ja) | 2016-08-05 | 2018-02-08 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| US11453726B2 (en) | 2016-09-15 | 2022-09-27 | Quadrucept Bio Limited | Multimers, tetramers and octamers |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| CN111094333A (zh) | 2017-06-01 | 2020-05-01 | 斯图加特大学 | 异源二聚化的Ig结构域 |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| CN109468278A (zh) | 2017-09-08 | 2019-03-15 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| MX2020012124A (es) | 2018-05-14 | 2021-04-19 | Immunocore Ltd | Polipeptidos de unión bifuncional. |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| MX2022000667A (es) | 2019-07-15 | 2022-07-21 | Neogene Therapeutics B V | Metodo para aislar genes tcr. |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| EP4025598A1 (en) | 2019-09-06 | 2022-07-13 | Eli Lilly and Company | Proteins comprising t-cell receptor constant domains |
| US20220396635A1 (en) | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| EP4034570A4 (en) | 2019-09-27 | 2023-10-25 | Agenus Inc. | HETERODIMERIC PROTEINS |
| AU2020384374A1 (en) | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| EP4061827A1 (en) | 2019-11-18 | 2022-09-28 | BioNTech SE | Prame tcr receptors and uses thereof |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| US20230130925A1 (en) | 2020-03-16 | 2023-04-27 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| EP4188416A4 (en) | 2020-07-27 | 2024-08-21 | Arizona Board of Regents on behalf of the University of Arizona | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLDED POLYPEPTIDES FROM SUBSTITUTION TRANSLATIONAL INITIATION AND TERMINATION |
| US20230374140A1 (en) | 2020-10-09 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| AU2021408160A1 (en) | 2020-12-21 | 2023-06-29 | Zymeworks Bc Inc. | Stabilized tcr constructs and methods of use |
| AU2022224066A1 (en) | 2021-02-19 | 2023-09-07 | Angeles Therapeutics, Inc. | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro not_active IP Right Cessation
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro not_active IP Right Cessation
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en not_active Abandoned
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019023184A5 (https=) | ||
| JP2020530762A5 (https=) | ||
| HRP20211744T1 (hr) | Poboljšana molekula polipeptida dvostruke specifičnosti | |
| Brinkmann et al. | The making of bispecific antibodies | |
| JP6936497B2 (ja) | 多価Ｆｖ抗体 | |
| CA2963615C (en) | ANTIBODIES WITH A DOMAIN EXCHANGE | |
| CA3199447A1 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| JP2018526981A5 (https=) | ||
| JP2020529410A5 (https=) | ||
| US20240059786A1 (en) | Anti-cd28 x anti-trop2 antibodies | |
| US20250043001A1 (en) | Anti-cd28 compositions | |
| JP2021529539A5 (https=) | ||
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| WO2022125986A1 (en) | Orthogonal mutations for heterodimerization | |
| JP2021019626A5 (https=) | ||
| TH2001000191A (th) | โมเลกุลโพลีเปปไทด์ความจำเพาะคู่ที่ปรับปรุง | |
| HRP20210759T1 (hr) | Poboljšana molekula polipeptida dvostruke specifičnosti | |
| KR20260042160A (ko) | 이중특이적 폴리펩티드 분자 | |
| JP2026514025A (ja) | 抗ｃｄ２８×抗ｅｎｐｐ３抗体 | |
| CN121969645A (zh) | 用于将免疫球蛋白重定向至免疫细胞的组合物 | |
| JPWO2020006568A5 (https=) | ||
| WO2025029975A1 (en) | Compositions for redirecting immunoglobulins to immune cells | |
| HK1240236A1 (en) | Cd3 binding domain |